---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096673"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:23:23.687940+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Metagenomi declares MGX-001 DC for hemophilia A; cash $299.9M into 2027

## Summary
- Declared MGX-001 as lead development candidate for hemophilia A; 12-month NHP data accelerated to September 2024.
- Cash, cash equivalents and marketable securities of $299.9M at June 30, 2024; runway into 2027.
- R&D expense $28.3M in Q2 2024 vs $22.7M in Q2 2023; G&A expense $8.6M vs $6.6M.
- All four Ionis Wave 1 cardiometabolic programs in lead optimization; targeting 1–2 DC nominations in 2025.
- Deprioritizing PH1 and ALS programs; pipeline guidance revised through year-end 2025.

## SEC filing metadata
- accession: 0000950170-24-096673
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000095017024096673/0000950170-24-096673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000095017024096673/mgx-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096673
- JSON: https://secwatch.observer/filing/0000950170-24-096673.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096673.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.